tbuckley/cabot-search huggingface dataset:
THE CARE AND FEEDING OF INFANTS
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Materia Medica and Therapeutics, for Physicians and Students.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conjunctivitis in dupilumab clinical trials
Authors: B. Akinlade, E. Guttman‐Yassky, M. Bruin‐Weller, E.L. Simpson, A. Blauvelt, M.J. Cork, E. Prens, P. Asbell, E. Akpek, J. Corren, C. Bachert, I. Hirano, J. Weyne, A. Korotzer, Z. Chen, T. Hultsch, X. Zhu, J.D. Davis, L. Mannent, J.D. Hamilton, A. Teper, H. Staudinger, E. Rizova, G. Pirozzi, N.M.H. Graham, B. Shumel, M. Ardeleanu, A. Wollenberg
Journal: British Journal of Dermatology (2019)

Conjunctivitis is a common condition that causes the eye to become red, itchy and oozing. It is common in patients with atopic dermatitis (also called eczema), and in other allergic diseases, including asthma. Apart from allergies, conjunctivitis can also be caused by infections, chemicals, irritants, and other diseases. Dupilumab is a prescription medicine approved in the USA for people 12 years and older with moderate‐to‐severe AD uncontrolled by topical (applied to the skin) prescription medicines or who cannot use topical medicines, for adults in other countries whose AD is uncontrolled with existing therapies, and for people 12 years and older for maintenance treatment of moderate‐to‐severe asthma uncontrolled with their current medicines. Dupilumab blocks activity of specific substances that cause these allergic diseases. In most AD studies, more dupilumab‐treated patients had conjunctivitis than patients on placebo (dummy drug). To investigate this effect, the authors assessed rates, risk factors, severity, and outcomes of conjunctivitis in 11 dupilumab studies in AD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis (EoE). In 5 of 6 AD studies, dupilumab‐treated patients were more likely to get conjunctivitis than placebo‐treated patients. No conjunctivitis was confirmed to be caused by infection, and it does not seem to be allergic in nature. Patients who entered these studies with more severe AD or who previously had conjunctivitis were more likely to get conjunctivitis. In asthma and CRSwNP studies, conjunctivitis rates were less frequent for both dupilumab and placebo than in AD studies, and were similar for dupilumab and placebo. In the EoE study, nobody had conjunctivitis. In all studies, conjunctivitis was mostly mild to moderate; most cases recovered during the treatment period. Causes of conjunctivitis in dupilumab‐treated patients require further study.
British Medical Journal, London
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the editors
Authors: Lucy Bird, Kirsty Minton, Olive Leavy, Yvonne Bordon, Gemma Ryan, Karen Irving, Man Tse, Lewis Packwood, Simon Bradbrook, Susanne Harris, Vicky Summersby, Patrick Managing, Judith Shadwell, Simon Fenwick, Natalie Smith, Jacques Smit, Laura Corns, Deborah Anthony, Marketing Managers, Tim Redding, Leah Rodriguez
Journal: Nature reviews. Immunology (2010)
A NEW EAR BASIN
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QOL-05. E-SURVEY OF CURRENT INTERNATIONAL PHYSIOTHERAPY PRACTICE FOR CHILDREN WITH ATAXIA FOLLOWING SURGICAL RESECTION OF POSTERIOR FOSSA TUMOUR
Authors: Helen Hartley, Bernie Carter, Lisa Bunn, Ram Kumar, Elizabeth Cassidy, Steven Lane, Barry Pizer
Journal: Neuro-Oncology (2018)

To determine current international practice regarding physiotherapy input for children with posterior fossa tumours. An e-survey primarily composed of closed questions covering the following domains; participant demographics, treatment and intervention, virtual training, intensity/timing of treatment, aims and outcomes of physiotherapy was piloted and refined. It was distributed internationally to physiotherapists via 6 key groups; (Paediatric Oncology Physiotherapy Network (POPs), Association of Paediatric Chartered Physiotherapists (APCP), European Paediatric Neurology Society (EPNS), International Society of Paediatric Oncology (SIOP)-Europe Brain Tumour Group, Posterior fossa society (PFS), Pediatric Oncology Special Interest Group (American Physical Therapy Association). Data were analysed descriptively. 84 physiotherapists participated: UK (n=53), rest of Europe (n=22), USA/Canada (n=9). The most common physiotherapy interventions used were balance exercises, proximal control activities, gait re-education, and task specific training. The most frequently used adjuncts to treatment were mobility aids and orthotics. A lack of clinical guidelines and research evidence in this area was highlighted. Frequent challenges raised regarding physiotherapy treatment in this area were; reduced availability of physiotherapy input following discharge from the acute setting, lack of evidence, impact of adjuvant treatment (e.g. chemotherapy/radiotherapy), and psychosocial impact. This e-survey provides an initial scoping review of international physiotherapy practice in this area. It demonstrates the wide range of intervention types used and highlights the lack of clinical evidence in this area. The results raise the need for further research in this field to help with the development of physiotherapy guidelines in children with posterior fossa tumours.
A Wisconsin Diploma Mill.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review The Compleat Pediatrician: Practical, diagnostic, therapeutic and preventive pediatrics . By Wilburt C. Davison, D.Sc., M.D. Fourth edition. 8°, cloth, 256 pp. Durham, N. C.: Printed by Seeman Printery for Duke University Press, 1943. $3.75 by check with order, or for $4.00 on credit.
Journal: New England Journal of Medicine (1944)
Infographic. Consensus recommendations on the classification, definition and diagnostic criteria of hip-related pain in young and middle-aged active adults from the International Hip-related Pain Research Network, Zurich 2018
Authors: Michael P Reiman, Rintje Agricola, Joanne L Kemp, Joshua J Heerey, Adam Weir, Pim van Klij, Ara Kassarjian, Andrea B Mosler, Eva Ageberg, Per Hölmich, Kristian Marstrand Warholm, Damian Griffin, Sue Mayes, Karim M Khan, Kay M Crossley, Mario Bizzini, Nancy Bloom, Nicola C Casartelli, Laura E Diamond, Stephanie Di Stasi, Michael Drew, Daniel J Friedman, Matthew Freke, Sion Glyn-Jones, Boris Gojanovic, Marcie Harris-Hayes, Michael A Hunt, Franco M Impellizzeri, Lasse Ishøi, Denise M Jones, Matthew G King, Peter R Lawrenson, Michael Leunig, Cara L Lewis, Nicolas Mathieu, Håvard Moksnes, May Arna Risberg, Mark J Scholes, Adam I Semciw, Andreas Serner, Kristian Thorborg, Adam Virgile, Tobias Wörner, H Paul Dijkstra
Journal: British Journal of Sports Medicine (2020)
Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
Authors: Yian Wang, Qijia Yan, Yongzhen Mo, Yuhang Liu, Yumin Wang, Shanshan Zhang, Can Guo, Fuyan Wang, Guiyuan Li, Zhaoyang Zeng, Wei Xiong
Journal: Molecular Cancer (2022)

Abstract Background Circular RNAs play an important role in tumor genesis and progression, but they have not been sufficiently studied in patients with nasopharyngeal carcinoma (NPC). Methods The circular RNA, circCAMSAP1, was screened in NPC cells by RNA sequencing analysis. The expression of circCAMSAP1 in NPC tissues was examined by real-time quantitative polymerase chain reaction (RT-qPCR) and in situ hybridization. Wound-healing, transwell, MTT and flow cytometry assays, and nude mouse tumor models were used to explore the effect of circCAMSAP1 on proliferation and metastasis of NPC in vitro or in vivo. The downstream proteins regulated by circCAMSAP1 were screened using mass spectrometry. The interaction between circCAMSAP1 and the SERPINH1 mRNA was identified using the circular RNA immunoprecipitation method and the luciferase reporter assay. The interaction between SERPINH1 and transcription factor c-Myc was verified through Co-immunoprecipitation (Co-IP) and immunofluorescence. The effect of c-Myc on the generation of circCAMSAP1 was examined through RT-qPCR and chromatin immunoprecipitation. Finally, the splicing factors that promote the production of circCAMSAP1 were explored by RT-qPCR and RNA immunoprecipitation (RIP). Results We found that circCAMSAP1 was highly expressed in NPC tissues and promoted NPC proliferation and metastasis. Additionally, circCAMSAP1 promoted SERPINH1 expression through improved SERPINH1 mRNA stability by binding to the 3′-untranslated region (3’UTR) of SERPINH1 . Highly expressed SERPINH1 reduced the ubiquitination-degradation rate of c-Myc, causing increased tumorigenesis. Meanwhile, c-Myc, cooperating with splicing factor 10 (SRSF10), could also promote CAMSAP1 pre-mRNA transcription and back-splicing, forming a positive feedback of circCAMSAP1 production, resulting in the proliferation and metastasis of NPC. Conclusions Our findings revealed that circCAMSAP1 promotes NPC proliferation and metastasis by binding to the 3’UTR of SERPINH1 , suggesting that the positive feedback of circCAMSAP1 -SERPINH1-c-Myc may serve as a prognostic biomarker or therapeutic target in patients with NPC.
Obstetrics and Gynecology, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
Authors: Xue Li, Francisco Tsz Tsun Lai, Gilbert T. Chua, Mike Yat Wah Kwan, Yu Lung Lau, Patrick Ip, Ian Chi Kei Wong
Journal: JAMA Pediatrics (2022)

This cohort study assesses the association between the single-dose COVID-19 BNT162b2 vaccination regimen and myocarditis risk among vaccinated adolescents in Hong Kong before and after the single-dose policy.
Complications of acupuncture
Authors: H. Carron
Journal: JAMA (1974)

Advocates of acupuncture therapy have claimed that no danger exists in acupuncture and that it can never be harmful. The inappropriate use of this treatment and its performance without adequate supervision, however, may result in complications that can be disfiguring, painful, and life-threatening. Six such incidents are described. It is recommended that the procedure be considered experimental and performed only in a study setting. Patients undergoing such therapy should be advised of its potential hazards. (<i>JAMA</i>228:1552-1554, 1974)
Channelopathies
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Population-Based Survey for Drug Resistance of Tuberculosis—Mexico, 1997
Journal: JAMA (1998)

The World Health Organization (WHO) estimates that 90 million cases of tuberculosis (TB), resulting in 30 million deaths, will occur during the 1990s. To address this problem, WHO has recommended a comprehensive strategy of directly observed treatment, short-course (DOTS). Although DOTS results in cure rates of > or =80%, the worldwide emergence of strains of Mycobacterium tuberculosis (MTB) resistant to antimycobacterial agents threatens this strategy for TB control. In 1994, WHO and the International Union Against Tuberculosis and Lung Disease (IUATLD) proposed the establishment of a global surveillance program to monitor drug resistance. In 1997, the Secretary of Health of Mexico, in collaboration with CDC, developed and implemented a national survey of drug resistance for TB as part of the global project on TB drug resistance. This report describes study results for three states in Mexico (Baja California, Oaxaca, and Sinaloa) and presents the first population-based TB drug-resistance data available for that country.
Covid-19: Vaccine programme a success, but staff burnout is a major risk, auditors warn
Authors: Gareth Iacobucci
Journal: BMJ (2022)

Vaccine programme a success, but staff burnout is a major risk, auditors warn Gareth IacobucciThe UK's covid-19 vaccination programme has been a success and has delivered value for money so far, but future success could be undermined by staff burnout and constrained capacity, the UK's public spending watchdog has warned.
Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment
Authors: Ruijie Chen, Yuan-Yuan Zhai, Lining Sun, Zeqing Wang, Xing Xia, Qing Yao, Longfa Kou
Journal: Asian Journal of Pharmaceutical Sciences (2022)

Psoriasis is a common chronic immune-mediated skin disease characterized by hyperproliferation and aberrant differentiation of keratinocytes and massive infiltration of inflammatory immune cells. Recent studies showed that Signal Transducer and Activator of Transcription 3 (STAT3), which plays an important role in cell survival, proliferation, differentiation, angiogenesis, and immune responses, is constitutively activated in epidermal keratinocytes of human psoriatic skin lesions. In addition, STAT3 promotes the differentiation and expansion of T cells and facilitates cytokine production, thereby exacerbating the condition of psoriasis. Alantolactone (ALT) is a sesquiterpene lactone compound that could selectively suppress STAT3 activation, but its effectiveness and application in psoriasis treatment have not been determined. In this study, we developed ALT loaded chitosan/hyaluronic acid nanoparticles (CHALT), and investigated its therapeutic potential for psoriasis therapy. CHALT effectively abrogated the hyperproliferation by inducing ROS-mediated apoptosis with loss of mitochondrial membrane potential, and also inhibited IL-6-induced STAT3 signaling activation and inflammatory reaction in HaCaT cell line. In an Imiquimod (IMQ)-induced psoriasis model, the topical treatment of psoriasis lesions with CHALT effectively attenuated the STAT3 hyperactivation within keratinocytes and ameliorated the symptoms of psoriasis. In addition, it was found that CHALT restricted the recruitment of immune cells. These results indicated that ALT-based nanoformulation CHALT holds great potential for psoriasis therapy.
Editorial Board
Authors: Donald Leung, Stanley Szefler, Colo Associate, Andrea Apter, Pedro Philadelphia, Bruce Avila, Baltimore Bochner, Joshua Boyce, Robert Bush, Fred Finkelman, Dennis Ledford, Tampa Fla, Deborah Meyers, Luigi Notarangelo, David Peden, Harald Renz, Marburg Germany, Marc Rothenberg, William Shearer, Scott Sicherer, New York, Donata Vercelli, Erika Von Mutius, Germany Munich, Vernon Statistics Editor, Hershey Chinchilli, John Atkinson, St Louis, A Burks, Mitchell Grayson, Milwaukee Wis, Simon Hogan, Hirohisa Saito, Talal Chatila, Los Angeles, Elizabeth Matsui, Thomas Platts-Mills, Gordon Bloomberg, Larry Borish, Angela Haczku, Jordan Orange, Darryl Zeldin, Leonard Bacharier, Sten Dreborg
Journal: Journal of Allergy and Clinical Immunology (2011)
Profiling Differential Responses to Pan-HER Inhibition
Journal: Cancer Discovery (2017)

Abstract Findings from the phase II SUMMIT basket trial indicate that among patients with solid cancers harboring HER2/3 mutations, responses to the investigational pan-HER inhibitor neratinib vary by specific alteration and tumor type. Neratinib showed promising single-agent activity in breast, biliary tract, and cervical cancers, but was ineffective against bladder and colorectal cancers; among a small subset of patients with HER3 mutations, no responses were seen.
Corrigendum
Journal: Neuro-Oncology (2016)

Additional criteria apply.Please refer to protocol 14379-201 for full inclusion and exclusion criteria.† Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IGF-1R, insulin-like growth factor 1 receptor; KPS, Karnofsky Performance Scale; RT, radiotherapy; SOC, standard of care; TMZ, temozolomide.